Abstract: In alternative embodiments, provided are methods for treating and ameliorating a cancer, or recurrence of a cancer such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 (or rebecsinib) and second drug such as an ATP-competitive protein tyrosine kinase inhibitor such as dasatinib. In alternative embodiments, provided are methods for the in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 and second drug. In alternative embodiments, provided are methods for the in vivo inhibition pre-leukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 and second drug.

Abstract: This disclosure provides apparatus, systems, and methods for updating display devices. In one aspect, a display can switch between a plurality of display modes based at least in part on a spatial distribution of changed image regions over a number of frames of an image to be displayed.

Abstract: Apparatus and methods are described for establishing a connection to a subscriber access network, such as a 3G network, over and untrusted network, such as a wireless LAN. A stream ID is assigned to a mobile device upon initialization of the device, and the stream ID remains active until the device powers down, loses WLAN coverage, or de-registers with the network. Both voice and data calls may be routed over the tunnel using the assigned stream ID.

Abstract: Apparatus and methods are described for establishing a connection to a wireless subscriber network over a wireless LAN. A secure tunnel is established between a PDIF and a mobile station. Both voice and data calls are exchange via the tunnel. Voice calls are forwarded to a SIP GW while data calls are routed to the Internet.